65 Biggest Movers From Yesterday

Gainers

• Society Pass Incorporated SOPA shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index.
• Bluerock Residential Growth REIT, Inc. BRG surged 76.2% to close at $27.20. Blackstone agreed to buy Bluerock Residential Growth REIT in a deal valued at $3.6 billion, extending its push into U.S. rental housing.
• Can-Fite BioPharma Ltd. CANF rose 69.3% to settle at $2.15 after the company announced a liver cancer patient was cleared of all cancer lesions.
• Verso Corporation VRS shares jumped 34.9% to close at $27.04 after the company announced it would be acquired by BillerundKorsnas for $27 per share.
• AeroClean Technologies, Inc. AERC gained 33.7% to settle at $11.31.
• AeroClean Technologies recently announced plans to install Pūrgo devices at MADabolic Jupiter.
• Cue Health Inc. HLTH jumped 28.9% to settle at $12.63. Cue Health recently appointed Nitin Duggal as its first Chief Marketing Officer.
• Galera Therapeutics, Inc. GRTX rose 28% to settle at $3.79. Citigroup maintained Galera Therapeutics with a Buy and raised the price target from $11 to $20.
• BioDelivery Sciences International, Inc. BDSI gained 26.9% to close at $3.30. BioDelivery Sciences said the US District Court issued opinion in favor of the company in patent litigation against Alvogen.
• Roivant Sciences Ltd. ROIV climbed 23.5% to settle at $13.52 after gaining 18% on Friday.
• Lucira Health, Inc. LHDX gained 22.9% to close at $6.70.
• HeartBeam, Inc. BEAT jumped 21.5% to settle at $3.56. Benchmark initiated coverage on BioTelemetry with a Speculative Buy rating and announced a price target of $9.
• Lineage Cell Therapeutics, Inc. LCTX gained 21.2% to close at $2.57. Lineage Cell Therapeutics entered into an exclusive worldwide collaboration and license agreement with Roche Holdings’ Genentech to develop and commercialize retinal pigment epithelium (RPE) cell therapy.
• Innovid Corp. CTV jumped 20.7% to settle at $8.15. Evercore ISI Group recently initiated coverage on Innovid with an Outperform rating and announced a price target of $10.
• StarTek, Inc. SRT climbed 20.6% to settle at $4.75.
• The Oncology Institute, Inc. TOI gained 19.6% to close at $7.63.
• Quotient Limited QTNT rose 19.5% to close at $2.70. Quotient recently won a $77 million Defense Logistics Agency contract.
• Local Bounti Corporation LOCL surged 19% to settle at $6.44.
• Fortuna Silver Mines Inc. FSM gained 17.7% to close at $3.79 after the company announced the SEMARNAT granted a twelve year extension of the environmental impact authorization at the San Jose Mine, located in Oaxaca, Mexico.
• Aridis Pharmaceuticals, Inc. ARDS surged 17.6% to settle at $2.54. Aridis Pharmaceuticals recently reported a Q3 loss of $1.94 per share.
• New Pacific Metals Corp. NEWP gained 17.6% to close at $3.01.
• Talaris Therapeutics, Inc. TALS jumped 17.3% to settle at $14.85 after the stock was added to the Nasdaq Biotechnology Index.
• Energy Focus, Inc. EFOI gained 16.9% to close at $3.88.
• Intra-Cellular Therapies, Inc. ITCI rose 15.8% to close at $45.35 after the company's Caplyta was approved by the FDA for bipolar depression.
• Preferred Apartment Communities, Inc. APTS gained 15.2% to settle at $16.57.
• Biomea Fusion, Inc. BMEA surged 14.4% to close at $8.26. Oppenheimer recently initiated coverage on Biomea Fusion with an Outperform rating and announced a price target of $22.
• Lottery.com Inc. LTRY gained 14.1% to settle at $5.99.
• Backblaze, Inc. BLZE surged 13.6% to close at $19.49.
• Backblaze recently posted a Q3 loss of $0.32 per share.
• BP Midstream Partners LP BPMP rose 13.3% to close at $14.63. BP announced agreement to acquire remaining stake in BP Midstream Partners, Reuters reported.
• TeraWulf Inc. WULF jumped 13.1% to settle at $14.65.
• Limelight Networks, Inc. LLNW jumped 12% to settle at $3.63. Raymond James upgraded Limelight Networks from Market Perform to Strong Buy.
• Calliditas Therapeutics AB CALT gained 11.9% to close at $26.26 after HC Wainwright & Co maintained a Buy rating on the stock and raised its price target from $52 to $62. Calliditas Therapeutics recently announced it was granted by the FDA accelerated approval of TARPEYO to reduce proteinuria in lgA nephropathy.
• GBS Inc. GBS climbed 11.1% to settle at $1.40 after dipping 23% on Friday. GBS recently announced application for FDA breakthrough device designation to fast track rapid saliva glucose test.
• CIT Group Inc. CIT gained 10% to close at $50.94. First Citizens recently announced receipt of regulatory approvals for deal with CIT.
• argenx SE ARGX jumped 9% to settle at $337.51 after the company announced the FDA approved VYVGART for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
• KemPharm, Inc. KMPH gained 6.8% to close at $8.31 as the company reported authorization of $50 million buyback.

Check out these big penny stock gainers and losers

Losers

• Summit Therapeutics Inc. SMMT shares tumbled 48% to close at $2.59 on Monday after reporting topline results for Phase III Ri-CoDIFy study for C. Difficile infection. The company said Ri-CoDIFy did not meet primary endpoint.
• Insignia Systems, Inc. ISIG dropped 35.1% to settle at $11.50.
• Nutriband Inc. NTRB fell 23.6% to settle at $3.14.
• Optical Cable Corporation OCC fell 21% to close at $5.09 after the company reported Q4 earnings results.
• PARTS iD, Inc. ID fell 19.2% to settle at $2.15.
• Immix Biopharma, Inc. IMMX declined 18.8% to close at $3.25 amid post-IPO volatility.
• Bellerophon Therapeutics, Inc. BLPH dropped 18.5% to close at $2.60. Bellerophon Therapeutics jumped around 35% on Friday after topline data from Phase 2 study (PULSE-PHPF-002) evaluating the acute hemodynamic benefit of INOpulse via right heart catheterization for pulmonary hypertension associated with sarcoidosis (PH-Sarc).
• Vera Therapeutics, Inc. VERA dropped 18.1% to close at $20.27. Vera Therapeutics recently reported the purchase of monoclonal antibody from Pfizer.
• Aemetis, Inc. AMTX declined 18.1% to settle at $12.21.
• Tuya Inc. TUYA fell 17.8% to close at $5.37.
• Blue Star Foods Corp. BSFC shares dropped 17.7% to settle at $2.05. Blue Star Foods recently announced plans to acquire the assets of Gault Seafood, LLC.
• CNFinance Holdings Limited CNF shares declined 16.1% to close at $3.86.
• Mawson Infrastructure Group, Inc. MIGI dropped 15.9% to settle at $7.26.
• Rubius Therapeutics, Inc. RUBY fell 15.5% to settle at $10.63.
• Sociedad Química y Minera de Chile S.A. SQM dropped 15.3% to close at $47.38.
• Vicarious Surgical Inc. RBOT shares declined 15.2% to settle at $9.97.
• Spruce Biosciences, Inc. SPRB fell 15.1% to close at $4.27. Spruce Biosciences shares jumped more than 102% on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15 price target.
• Cassava Sciences, Inc. SAVA dropped 15% to settle at $36.77.
• Humanigen, Inc. HGEN fell 15% to close at $3.75.
• Clarus Therapeutics Holdings, Inc. CRXT fell 14.9% to close at $3.14.
• Nuvalent, Inc. NUVL fell 14.5% to close at $19.54.
• ForgeRock, Inc. FORG fell 14.1% to close at $21.71. The company recently disclosed two significant new features to the ForgeRock Identity Cloud called Organizations and Themed User Journeys.
• Stronghold Digital Mining, Inc. SDIG fell 13.7% to close at $10.87. Stronghold Digital Mining said it acquired 9,080 bitcoin miners and secured $54 million equipment financing.
• Regis Corporation RGS dropped 12.6% to settle at $2.08.
• Argo Blockchain plc ARBK fell 12.3% to close at $11.38 after rising around 5% on Friday.
• Ipsidy Inc. AUID fell 10.8% to close at $14.92.
• Sono Group N.V. SEV declined 10.8% to close at $10.13.
• Zhihu Inc. ZH shares fell 9.6% to close at $5.17. China summoned Zhihu for unlawful release of information.
• California Resources Corporation CRC fell 9% to close at $38.63.
• Eloxx Pharmaceuticals, Inc. ELOX shares fell 8.4% to close at $0.6764. Eloxx Pharmaceuticals shares climbed 12% on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $4 price target.